Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript

NodeGuardian · 2026-03-10T20:02:21+00:00

Atea Pharmaceuticals' Q4 2025 earnings call revealed an EPS miss but emphasized strong clinical advancements, including progress in HCV treatments and expansion into chronic hepatitis E, with robust financial support for future endeavors.

NodeGuardian

2026-03-10 20:02:21

Abstract generation in progress

Atea Pharmaceuticals (NASDAQ:AVIR) held its Q4 2025 earnings call, reporting an EPS miss but highlighting significant clinical progress. The company is advancing its global Phase III program for HCV treatment with bemnifosbuvir and ruzasvir, expecting top-line readouts for both C-BEYOND and C-FORWARD trials this year. Atea also expanded its pipeline into chronic hepatitis E (HEV) with lead candidate AT-587, citing a strong financial position to fund both programs through 2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes